Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced preliminary unaudited revenues for the third quarter ended September 30, 2026.

Preliminary Financial Highlights:

  • Total Revenue: Expected to be in the range of $9.8 million to $10.0 million.

     
  • Year-over-Year Growth: Expected to increase approximately 85% to 89% compared with $5.3 million in the third quarter of 2025.

     
  • Sequential Quarter-over-Quarter Growth: Expected to increase approximately 292% to 300% compared with $2.5 million in the second quarter of 2026.